Novartis' New Heart Drug Expected To Be A Hit

Novartis AG (ADR) (NVS) announced today that it will showcase its heart failure drug LCZ696 on August 31 at the annual meeting of the European Society of Cardiology (ESC). ESC is considered to be the world's largest cardiology conference.